Alpha Tau Reports Highly Positive Interim Glioblastoma Trial Results: 2 Complete Responses, 1 Stable Disease

summarizeSummary

Alpha Tau Medical announced highly positive interim results from its REGAIN trial for recurrent glioblastoma, with two patients achieving complete response and one showing stable disease with significant tumor reduction.

check_boxKey Events

• Strong Efficacy in Recurrent Glioblastoma

  Interim data from the REGAIN trial (first 3 patients) showed 2 complete responses (CR) and 1 stable disease (SD) with a 30% tumor size reduction in patients with recurrent glioblastoma (GBM).

• Manageable Safety Profile

  No unanticipated side effects were noted. Two patients experienced seizures, which were consistent with their medical history and improved to baseline with steroid management.

• Advancing Clinical Development

  The company plans to complete enrollment of 10 patients in this pilot study, pending FDA review of the initial safety and efficacy data.

• Reinforces Prior Positive News

  This filing provides the detailed clinical presentation supporting the highly positive interim results for recurrent glioblastoma announced earlier today, May 11, 2026.

auto_awesomeAnalysis

This filing details highly encouraging early clinical data for Alpha Tau's Alpha DaRT therapy in recurrent glioblastoma (GBM), a severe and difficult-to-treat brain cancer with high unmet medical need. Achieving complete responses in two out of three patients, and stable disease with significant tumor reduction in the third, represents a strong efficacy signal for a pilot study. The manageable safety profile, with reported seizures consistent with patient history, further supports the therapy's potential. These results are critical for advancing the Alpha DaRT program and could significantly impact the company's valuation as it moves towards broader clinical development and potential regulatory approvals.